{"id":"zepatier-oral-product","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Elbasvir and grazoprevir work by binding to the NS5A and NS3/4A proteases of the hepatitis C virus, preventing the virus from replicating. This leads to a reduction in viral load and an improvement in liver function.","oneSentence":"Zepatier is a combination of elbasvir and grazoprevir, which are inhibitors of the hepatitis C virus NS5A and NS3/4A proteases, respectively.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:18.519Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotype 1 or 4"},{"name":"Chronic HCV infection, genotype 1a or 1b, without cirrhosis or with compensated cirrhosis"}]},"trialDetails":[{"nctId":"NCT02940496","phase":"PHASE2","title":"Pembrolizumab (MK-3475) in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-09","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection","enrollment":15},{"nctId":"NCT04048850","phase":"","title":"Zepatier in Patients with Substance Use","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2019-09-20","conditions":"Hepatitis C, Hiv, Coinfection, HIV","enrollment":25},{"nctId":"NCT02902120","phase":"PHASE4","title":"HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2017-05-01","conditions":"Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney","enrollment":21},{"nctId":"NCT02743897","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-05-01","conditions":"End Stage Renal Disease","enrollment":62},{"nctId":"NCT03379506","phase":"PHASE2","title":"Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-01-25","conditions":"HCV Infection","enrollment":57},{"nctId":"NCT03823911","phase":"PHASE4","title":"Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-11-18","conditions":"Cardiovascular Diseases, Hepatitis C, Hiv","enrollment":87},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT03496233","phase":"PHASE3","title":"Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo","startDate":"2018-09-19","conditions":"Chronic HCV Hepatitis","enrollment":75},{"nctId":"NCT03365635","phase":"PHASE4","title":"Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-09-22","conditions":"Hepatitis C, Hemodialysis, Nosocomial Infection","enrollment":6},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":1275},{"nctId":"NCT03146741","phase":"PHASE1, PHASE2","title":"Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-05-16","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT03236506","phase":"PHASE2","title":"A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2018-01-19","conditions":"Hepatitis C","enrollment":129},{"nctId":"NCT02133131","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-13","conditions":"Hepatitis C","enrollment":143},{"nctId":"NCT02105701","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Hepatitis C Infection","enrollment":420},{"nctId":"NCT03578640","phase":"PHASE3","title":"Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4","status":"COMPLETED","sponsor":"King Fahad Medical City","startDate":"2018-07-01","conditions":"Hepatitis C, Chronic","enrollment":30},{"nctId":"NCT04546802","phase":"PHASE3","title":"HepATocellular Cancer Hcv Therapy Study","status":"WITHDRAWN","sponsor":"Bayside Health","startDate":"2019-09","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma","enrollment":""},{"nctId":"NCT03381859","phase":"PHASE4","title":"Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2019-12-01","conditions":"Hepatitis C Virus Infection, Response to Therapy of","enrollment":""},{"nctId":"NCT03420300","phase":"PHASE4","title":"EBR/GZR for HCV-1b Patients Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-06-05","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT02940691","phase":"PHASE4","title":"Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs","status":"TERMINATED","sponsor":"Kirby Institute","startDate":"2017-05-01","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT02886624","phase":"PHASE2","title":"Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2017-05-31","conditions":"Acute Hepatitis C, HIV","enrollment":30},{"nctId":"NCT04063839","phase":"","title":"HCV Treatment in a Low-threshold Clinic","status":"UNKNOWN","sponsor":"University Hospital, Akershus","startDate":"2015-01","conditions":"Hepatitis C, Substance Use Disorders","enrollment":300},{"nctId":"NCT03221582","phase":"PHASE4","title":"Impact of Hepatitis C Therapy and Bone Health","status":"TERMINATED","sponsor":"Dallas VA Medical Center","startDate":"2017-08-28","conditions":"Human Immunodeficiency Virus, Hepatitis C","enrollment":6},{"nctId":"NCT02601573","phase":"PHASE2","title":"Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-05","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT02251990","phase":"PHASE3","title":"Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-01-28","conditions":"Hepatitis C","enrollment":489},{"nctId":"NCT03186365","phase":"PHASE3","title":"8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2017-06-12","conditions":"Hepatitis C, Chronic","enrollment":82},{"nctId":"NCT02252016","phase":"PHASE3","title":"Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-10-22","conditions":"Hepatitis C","enrollment":159},{"nctId":"NCT02781649","phase":"PHASE4","title":"Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2016-07-20","conditions":"End-Stage Renal Disease, Hepatitis C","enrollment":10},{"nctId":"NCT02785666","phase":"PHASE3","title":"Swiss HCVree Trial","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2016-06","conditions":"Hepatitis C, HIV","enrollment":150},{"nctId":"NCT03407703","phase":"","title":"Hepatitis C (HCV) Cure and Kidney Health","status":"UNKNOWN","sponsor":"San Francisco Veterans Affairs Medical Center","startDate":"2018-03-27","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03143998","phase":"PHASE4","title":"Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-12","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zepatier"],"phase":"phase_3","status":"active","brandName":"Zepatier Oral Product","genericName":"Zepatier Oral Product","companyName":"Kaohsiung Medical University Chung-Ho Memorial Hospital","companyId":"kaohsiung-medical-university-chung-ho-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zepatier is a combination of elbasvir and grazoprevir, which are inhibitors of the hepatitis C virus NS5A and NS3/4A proteases, respectively. Used for Chronic hepatitis C virus (HCV) infection, genotype 1 or 4, Chronic HCV infection, genotype 1a or 1b, without cirrhosis or with compensated cirrhosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}